Loading...
XJPX
4530
Market cap1.94bUSD
Dec 05, Last price  
4,153.00JPY
1D
-0.31%
1Q
-5.05%
Jan 2017
-29.01%
Name

Hisamitsu Pharmaceutical Co Inc

Chart & Performance

D1W1MN
XJPX:4530 chart
P/E
13.88
P/S
1.94
EPS
299.13
Div Yield, %
1.07%
Shrs. gr., 5y
-2.17%
Rev. gr., 5y
2.04%
Revenues
156.01b
+10.09%
102,665,000,000109,791,000,000119,061,000,000124,655,000,000129,834,000,000137,184,000,000137,794,000,000142,772,000,000150,635,000,000156,743,000,000161,852,000,000145,925,000,000147,870,000,000143,408,000,000140,992,000,000114,510,000,000120,193,000,000128,330,000,000141,706,000,000156,006,000,000
Net income
21.76b
+55.76%
14,448,000,00015,847,000,00018,663,000,00019,120,000,00018,423,000,00020,956,000,00018,439,000,00018,809,000,00021,357,000,00018,784,000,00017,784,000,00020,395,000,00019,119,000,00019,204,000,00018,694,000,0009,250,000,0009,658,000,00011,742,000,00013,969,000,00021,758,000,000
CFO
18.77b
+3.17%
23,114,000,00012,228,000,00025,722,000,00022,382,000,00020,498,000,00036,342,000,00025,558,000,00032,485,000,00035,845,000,00023,232,000,00030,923,000,00019,910,000,00030,453,000,00015,772,000,00027,395,000,0005,289,000,00019,199,000,00012,727,000,00018,188,000,00018,765,000,000
Dividend
Feb 26, 202660 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
URL
https://www.hisamitsu.co.jp/
IPO date
Sep 01, 1962
Employees
2,769
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑022024‑022023‑022022‑022021‑022020‑022019‑022018‑022017‑022016‑02
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT